Drug intelligence / Profile preview

meningococcal conjugate vaccine, quadrivalent

Development stage: Approved
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Meningococcal conjugate vaccine, quadrivalent is an active immunizing agent used to prevent infection caused by Neisseria meningitidis serogroups A, C, W, and Y. The vaccine works by stimulating the body to produce antibodies against these specific serogroups of meningococcal bacteria. It does not protect against serogroup B meningococcal disease. The vaccine helps prevent meningococcal meningitis (infection of the brain and spinal cord) and meningococcemia (infection of the blood), which can be life-threatening or cause serious long-term disabilities.

Brand names: MenactraMenQuadfiMenveo
Other names: MenACWYmeningococcal vaccine, tetanus toxoid conjugate quadrivalent

Beyond the preview

Go deeper on meningococcal conjugate vaccine, quadrivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meningococcal conjugate vaccine, quadrivalent.

Explore the full profile